Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled A RANDOMIZED, 2-ARM, ...

There was no difference in risk for lenalidomide plus cyclophosphamide, lenalidomide plus dexamethasone, and melphalan alone. "These data suggest that the future role of oral melphalan in ...

Patients with untreated symptomatic MM were randomly assigned at a one-to-one-to-one ratio to lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 ...

Lenalidomide offers an exciting advance in the treatment of the 5q– MDS patient. It has the ability to alter the course of MDS by inducing hematologic and cytogenetic responses, resulting in ...

The combination of lenalidomide and dexamethasone (Len–Dex) is a commonly used initial therapy for newly diagnosed multiple myeloma (MM). Although the initial response rates and toxicity are ...

Contacts IR Contacts United States Ran Meir (267) 468-4475 Israel Yael Ashman 972 (3) 914-8262 PR Contacts United States Kelley Dougherty (973) 658-0237 Yonatan Beker (973) 264 7378 ...

Lenalidomide, an immunomodulatory agent with antiangiogenic and antineoplastic properties, is a standard treatment for initial and relapsed multiple myeloma.

A dose-adjusted lenalidomide regimen that included discontinuation of dexamethasone after 9 months appeared safe and led to similar outcomes as continuous lenalidomide plus dexamethasone among ...

1 Belada D, M.D., Ph.D., et al. A Phase 1b, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in ...

Editorial Lenalidomide in Myeloma — A High-Maintenance Friend Author: Ashraf Z. Badros, M.B., Ch.B. Author Info & Affiliations Published May 10, 2012 N Engl J Med 2012;366: 1836 - 1838 ...

Mayo Clinic. "Lenalidomide may delay onset of myeloma-related bone, organ damage." ScienceDaily. ScienceDaily, 28 October 2019. <www.sciencedaily.com / releases / 2019 / 10 / 191028104212.htm>.